Epilepsy Trial, Recruiting NCT04421846 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT04421846
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group 1 (Status Epilepticus):

  • You are 2 years old or older and are experiencing a prolonged or repeated seizure episode (known as status epilepticus)
  • You are covered by the French social security system (excluding the AME state medical assistance program)
  • You, or a family member on your behalf, have agreed and given written consent to take part
  • People under legal protection (such as guardianship) are also eligible to apply

Group 2 (Epilepsy linked to immune-related brain inflammation):

  • You are 2 years old or older and have seizure symptoms linked to a condition where the immune system attacks the brain (dysimmune encephalitis)
  • You are covered by the French social security system (excluding the AME state medical assistance program)
  • You, or a family member on your behalf, have agreed and given written consent to take part
  • People under legal protection (such as guardianship) are also eligible to apply

Group 3 (General epilepsy):

  • You are 18 years old or older and have epilepsy, but do not have prolonged seizure episodes or immune-related brain inflammation
  • You are covered by the French social security system (excluding the AME state medical assistance program)
  • You, or a family member on your behalf, have agreed and given written consent to take part
  • People under legal protection (such as guardianship) are also eligible to apply

Who may not be able to join:

Group 1:

  • Women who are pregnant or where pregnancy has been detected
  • Anyone who is currently detained or imprisoned
  • Anyone diagnosed with a known degenerative brain or nervous system disease

Group 2:

  • Women who are pregnant or where pregnancy has been detected
  • Anyone who is currently detained or imprisoned
  • Anyone who has already received treatment with corticosteroids (steroid medicines) or intravenous immunoglobulins (a treatment using antibodies given through a drip)

Group 3:

  • Women who are pregnant or where pregnancy has been detected
  • Anyone who is currently detained or imprisoned
  • Anyone currently experiencing prolonged or repeated seizure episodes (status epilepticus)
  • Anyone with a known degenerative brain disease, brain tumour, severe head injury, meningitis, bleeding around the brain, or stroke

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vincent NAVARRO, Pr, Hôpital Pitié Salpêtrière - Assitance Publique Hôpitaux de Paris

Phone: 01 42 16 19 40

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
25 November 2020
Est. completion
1 June 2033

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Identification of (i) antibodies in the plasma and in the cerebrospinal fluid of patients with dysimmune encephalitis and (ii) biomarkers for neuronal death in the plasma and in the cerebrospinal fluid of patients with status epilepticus

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov